- An integrative study using Swedish registries (SWEDCON,GUCH), RiksSvikt) for identification of outcomes and predictors of outcomes in adult patients with congenital heart disease. Edith Nagy/Lars Lund. Juni 2016. Stockholm
- Diagnostik och behandling av hjärtsvikt i primärvården. Björn Eriksson/Magnus Edner. 2016. Stockholm.
- Smoking, pulmonary disease and outcomes in HFrEF, HFmrEF and HFpEF. Marat Fudim. Juli 2017. Duke University USA/Stockholm
- Incidence, timing and characteristics of heart failure following chemotherapy for lymphoma. Sara Harrysson/Karin Ekström Smedby. Oktober 2017. Stockholm
- Age, gender and socioeconomic status as risk factors for non-adherence to heart failure medication; a register-based cohort study. Anna Ohlsson/Bertil Lindahl. Maj 2018. Uppsala.
- Sambanden mellan Diabetes typ 1 och typ 2 och HFrEF, HFmrEF och HFpEF samt deras prognostiska betydelse. Annika Rosengren/Maria Schaufelberger. Juni 2018. Göteborg
- Relevance and significance of left ventricular ejection fraction in heart failure: Phenotype derivation from the US PINNACLE registry linked to Medicare data and validation from the Swedish Heart Failure Registry linked to the Swedish National Patient and population registries. Hanna K Gaggin/James Januzzi. September 2018. Boston USA.
- From electronic health record to ejection fraction based heart failure phenotype: Development and validation of HER based algorithms for identifying HF subphenotypes (HFrEF/HFpEF). Alicia Uijl/Gianluigi Savarese. Oktober 2018. Utrecht/Stockholm
- Stroke prediction in chronic heart failure without atrial fibrillation – comparing different registries. Alicia Uijl/Gianluigi Savarese. Oktober 2018. Utrect/Stockholm
- Förlopp och sjuklighet vid kronisk andningsstörning – en registerbaserad populationsstudie. Magnus Ekström/Josefin Sundh. Oktober 2018. Karlskrona/Örebro
- Incidence of cancer in patients with heart failure: long term follow-up. Entela Bollano/Elmir Omerovic. November 2018. Göteborg
- Interaction between heart failure treatment dosage and blood pressure for clinical outcome. Nicolas Girerd/Lars Lund. December 2018. Nancy/Stockholm
- Role of cardiovascular and non-cardiovascular comorbidities in heart failure. Camilla Settergren/Gianluigi Savarese. Januari 2019. Stockholm
- The SW-EQ project: Analysis of EQ-5D profile data and EQ VAS scores across patient groups in the Swedish National Quality registers and use in developing alternative ways of summarizing EQ-5D data. Emma Naucler. Februari 2019. Göteborg
- Optimering av träning för kvinnor med bröstcancer – en randomiserad kontrollerad studie (OptiTrain). Yvonne Wengström. Mars 2019. Stockholm
- Bröstcancer och hjärtsvikt: Prevalens och behandling. En registerstudie över patienter med hjärtsvikts- och bröstcancerdiagnos. Laila Hubbert/Elham Hedayati. Maj 2019. Norrköping/Stockholm
- Jämförelse av patienter I SPIRRIT med patienter registrerade i RiksSvikt med avseende på riskmarkörer och utfall. Lars Lund. August 2019. Stockholm
- Predictors of NYHA class and their impact on outcome in heart failure. Data from the Swedish Heart Failure Registry. Benedikt Schrage/Gianluigi Savarese. September 2019.Hamburg/ Stockholm
- Metabola rubbningar och inflammation i relation till kronisk sjukdom, främst hjärt-kärl sjukdom. Njursjukdom, cancer, demenssjukdom, autoimmuna sjukdomar och psykisk ohälsa – epidemiologiska studier baserade på AMORIS-populationen. Niklas Hammar/Maria Feychting. December 2019. Stockholm
- Ärftlighet, familjefaktorer, boendemiljö och cancer; 1958-2018. Kristina Sundkvist/Henrik Ohlsson. Mars 2020. Lund
- Överlevnad efter hjärttransplantation – en nationell observationsstudie. Dennis Medved/Johan Nilsson. Mars 2020. Lund
- Interaktion mellan Covid-19 och kardiovaskulär sjukdom: epidemiologi, prognos och terapeutiska implikationer. Lars Lund/Gianluigi Savarese. Mars 2020. Stockholm
- Demografi och andra karakteristika, komorbiditet och riskfaktorer för Covid-19 insjuknande och prognos. Fredrik Nyberg. Juni 2020. Göteborg..
- Stockholm Creatinine Measurements (SCREAM) project. Jean-Jesus Carrero/Lars Lund. Augusti 2020. Stockholm
- Studier av orsaker, sjuklighet och behandlingsutfall vid sarkoidos. Marios Rossides/Johan Askling. Juni 2020. Stockhom
- Dödlighet på kort och medellång sikt efter åtgärd för brustet och/eller icke-brustet kroppspulsåderbråck i buken: 1. För olika operationstekniker, 2. För vitala respektive bräckliga patienter samt 3. För sjukhus med liten respektive stor verksamhetsvolym. Fredrik Lundgren/Thomas Troäng. Juli 2020. Kalmar/Karlskrona
- Personalized lifetime prediction of survival and treatment effects in patients with chronic heart failure and reduced ejection fraction. The LIFE-HF model. Pascal Burger/Gianluigi Savarese. Juli 2020. Stockholm
- Association of body mass index with mortality/morbidity in heart failure across ejection fraction phenotypes. Data from the Swedish Heart Failure Registry. Daniele Rodolico/ Gianluigi Savarese. April 2021. Stockholm
- Antiplatelet agents in Heart Failure, any prognostic role? Astrid Karlsson/Gianluigi Savarese. April 2021. Stockholm Stockholm
- Impact of adherence to guideline directed medical therapy on risk of mortality in patients with heart failure across ejection fraction spectrum in real world. Xiaojing Chen/ Michael Fu. Maj 2021. Chengdu – Sichuan/ Göteborg
- Causal association between body mass index and left ventricular mass index (LVMI) independent of blood pressure; Heart Failure implications Philip Sarajilic/Magnus Bäck. Juni 2021. Stockholm
- Timing and modalities of initiation/Up-titration of ARNI in patients hospitalized for HF vs outpatients with reduced ejection fraction heart failure: Real-world data from the Swedish Heart Faiure Registry. Chiara Cappelletto/Gianluigi Savarese. August 2021.
- Förekomst och betydelse av anemi för hjärtsviktpatienter som omhändertas inom primärvården. Anna Ugarph-Morawski/Magnus Edner. Augusti 2021. Stockholm
- Clustering in heart failure with reduced ejection fraction. Alicia Uijl/Lars Lund. September 2021. Stockholm
- Cancer in heart failure across the ejection fraction spectrum: epidemiology and association of cancer with cardiovascular treatments: Data from the Swedish Heart Failure Registry. Chiara Cappelletto/Entela Bollano. September 2021. Stockholm/Göteborg
- Karakterisering av hjärtsvikt; en analys av patienters fenotyper, etiologiska och prognostiska faktorer, mortalitet och morbiditet, och behandling. Gianluigi Savarese/Lars Lund. Oktober 2021. Stockholm
- Cardiac resynchronization therapy practice in heart failure vs electrophysiology settings/clinics in Europe. Paolo Gatti/Lars Lund. Oktober 2021. Stockholm
- Pharmacological treatment patterns and outcomes in patients with heart failure with and without type 2 diabetes across the ejection fraction spectrum. Francesca Musella/ Guila Ferrannini/Gianluigi Savarese. November 2021. Stockholm
- Phenomapping for identification of subgroups in heart failure with mildly reduced ejection fraction using data from the CHECK-HF and Swede-HF registry. Claartje Meijs/Alicia Uijl. November 2021. Utrect/Stockholm
- Pharmacological treatment patterns and outcomes in patients with heart failure with and without type 2 Diabetes across the ejection fraction spectrum. Francesca Musella/Gianluigi Savarese. November 2021. Stockholm
- Association between a hospitalization for heart failure and the initiation/discontinuation of guideline recommended tratments – an analysis from the Swedish Heart Failure Registry. Benedict Schrage/Gianluigi Savarese. Januari 2022. Hamburg/Stockholm
- Change in health-related quality of life over 1 year and outcomes in patients with heart failure related to age, sex and HF subtype: Data from the Swedish Heart Failure Registry. Claire Lawson/Anna Strömberg. Januari 2022. Leicester/Linköping
- Värdet av hälsa och införande av nya läkemedel. Naimi Johansson. Januari 2022. Örebro
- Diuretic therapy as a prognostic enrichment factor for clinical trials in patients with heart failure across the ejection fraction spectrum. Marat Fudim/Lars Lund. Januari 2022. Duke University/Stockholm
- se – The Swedish Cohort Consortium – Cycle 2. Christian Bruzelius/Johan Sundström. Februari 2022. Uppsala
- world eligibility of vericiguat according to trial, guidelines and labeling eligibility criteria. Data from the Swedish Heart Failure Registry. Ngoc V. Nguyen/Gianluigi Savarese. Februari 2022. Stockholm
- Treatment and prognostic predictors in new-onset vs long standing heart failure. Aniza Shahim/Camilla Hage. Mars 2022. Stockholm
- Valvular heart diseases and heart failure – prevalence, predisposing factors, temporal trends and prognostic impact of developing Valvular heart disease after heart failure and vice versa. Bahira Shahim/Lars Lund. April 2022. Stockholm
- Use of SGLT2i in heart failure patients across the ejection fraction spectrum. Peter Moritz Becher/Gianluigi Savarese. April 2022. Hamburg/Stockholm
- Hjärtinfarkt och stroke – insjuknande, dödlighet mellan 2002-2015. Lena Björck. April 2022. Göteborg
- Risk factors in cardiac arrest in patients with heart failure. Meena Thuccani/Peter Lundgren. Göteborg
- Dödlighet och dess orsak och påverkande faktorer hos patienter med hjärtsvikt. Antros Louca/Michael Fu. Juni 2022. Göteborg
- Registerstudie av komplikationer efter cancer hos barn, ungdomar och unga vuxna i Sverige. Laila Hubbert/Elham Hedayati/Joakim Alfredsson/ Bertil Ekman/Margaretha Stenmarker. Juni 2022. Linköping/Stockholm/Jönköping. Juni 2022.
- Association between use of RASi/ARNI and betablockers with mortality/morbidity in real world heart failure patients with HFmrEF. Data from the Swedish Heart Failure Registry. Davide Stolfo/Gianluigi Savarese. August 2022. Trieste/Stockholm
- SGLT2i:s are associated with reduced risk of mortality and re-admission in heart failure patients. Data from the Swedish Heart Failure Registry. Patric Karlström/Michael Fu. Oktober 2022. Jönköping/Göteborg
- The prognostic impact of sarcoidosis in patients with heart failure. Entela Bollano/Michael Fu. Oktober 2022. Göteborg
- Prior myocarditis in patients with heart failure . Does it matter. Entela Bollano/Michael Fu. Göteborg.
- Characterizing heart failure with supranormal ejection fraction. Laura Landucci/Gianluigi Savarese. Oktober 2022. Stockholm
- Phenotyping patients with heart failure for N-terminal pro-B-type natriuretic peptide concentrations and testing: Data from the Swedish Heart failure Registry. Giulia Ferrannini/Gianluigi Savarese. Stockholm
- Menopausal hormonbehandling i relation till risk för kroniska sjukdomar och förtida död. Karin Leander Karolinska Institutet, Stockholm. Juni 2023.
- Assessment of drug combinations within guideline-directed medical therapy: data from the Swedish Heart Failure Registry. Giulia Ferrannini /Gianluigi Savarese. Stockholm Augusti 2023
- Modern heart failure treatment are associated with reduced risk of mortality compared to conventional treatment: Real-life data from the Swedish Heart Failure registry 2013-2020. Michael Fu/Patric Karlström. Augusti 2023.